Payment overview · 2025
General Payments
$566.18
15 reported records · 13 companies
Healthcare provider profile · identity verified
Gardith Joseph, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · BROOKLYN, NY · NPI 1811928773
Verified facts
What the public records show
CMS Open Payments records show Gardith Joseph, M.D. received $566.18 in general payments during 2025 across 15 reported records.
Incyte Corporation accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jakafi, Orgovyx, Sarclisa, Xtandi.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Xtandi by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Pomalyst by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SARCLISA as an associated drug or biological on 7155 records involving 4028 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Sarclisa by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jakafi by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 17129 records involving 6223 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Orgovyx by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Incyte Corporation | Unresolved — no canonical attribution shown | $124.18 | 21.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $118.71 | 21.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $40.00 | 7.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $38.46 | 6.8% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $32.22 | 5.7% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $30.79 | 5.4% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $30.60 | 5.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.86 | 5.3% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.59 | 5.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.51 | 4.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.79 | 4.6% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $22.04 | 3.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.43 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $467.18 | 14 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $118.71 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $38.46 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $32.22 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $30.79 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $30.60 | 1 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $28.59 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $27.51 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $25.79 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $17.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORGOVYX orgovyx |
2025 | Orgovyx | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SARCLISA sarclisa |
2025 | Sarclisa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Xtandi xtandi |
2025 | Xtandi | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | SARCLISA open payments reported associated product |
CMS Open Payments — General Payments 7155 supporting records · 4028 recipient NPIs · example record 1233194888 |
Sarclisa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 17129 supporting records · 6223 recipient NPIs · example record 1176593507 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diphenhydramine Hcl | Diphenhydramine Hcl | 158 | 27 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 137 | 25 |
| Anastrozole | Anastrozole | 120 | 31 |
| Folic Acid | Folic Acid | 103 | 36 |
| Famotidine | Famotidine/Pf | 94 | 17 |
| Exemestane | Exemestane | 93 | 28 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosp/Pf | 82 | 17 |
| Xgeva | Denosumab | 68 | 14 |
| Darzalex | Daratumumab | 66 | suppressed |
| Gabapentin | Gabapentin | 64 | 22 |
| Xtandi | Enzalutamide | 62 | 11 |
| Dexamethasone | Dexamethasone | 51 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 49 | 19 |
| Jakafi | Ruxolitinib Phosphate | 49 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 47 | suppressed |
| Letrozole | Letrozole | 47 | 14 |
| Lactulose | Lactulose | 45 | 14 |
| Valacyclovir | Valacyclovir Hcl | 44 | 11 |
| Hydroxyurea | Hydroxyurea | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Abiraterone Acetate | Abiraterone Acetate | 36 | suppressed |
| Prednisone | Prednisone | 35 | suppressed |
| Procrit | Epoetin Alfa | 34 | 16 |
| Calquence | Acalabrutinib Maleate | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 15 |
| Imfinzi | Durvalumab | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Orgovyx | Relugolix | 26 | suppressed |
| Prolia | Denosumab | 26 | 17 |
| Carboplatin | Carboplatin | 25 | suppressed |
| Omeprazole | Omeprazole | 25 | suppressed |
| Revlimid | Lenalidomide | 23 | suppressed |
| Lenalidomide | Lenalidomide | 22 | suppressed |
| Truxima | Rituximab-Abbs | 20 | suppressed |
| Bortezomib | Bortezomib | 18 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 18 | suppressed |
| Jevtana | Cabazitaxel | 17 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 16 | suppressed |
| Oxaliplatin | Oxaliplatin | 16 | suppressed |
| Nivestym | Filgrastim-Aafi | 15 | suppressed |
| Pomalyst | Pomalidomide | 15 | suppressed |
| Zarxio | Filgrastim-Sndz | 15 | suppressed |
| Zoledronic Acid | Zoledronic Acid | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 14 | suppressed |
| Lupron Depot | Leuprolide Acetate | 14 | suppressed |
| Sarclisa | Isatuximab-Irfc | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Granisetron Hcl | Granisetron Hcl/Pf | 12 | suppressed |
| Verzenio | Abemaciclib | 12 | suppressed |
| Cyclophosphamide | Cyclophosphamide | 11 | suppressed |
| Gemcitabine Hcl | Gemcitabine Hcl | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $566.18 · 15 records | Incyte Corporation | BESREMI, Enhertu, Fabhalta, JAKAFI, KISQALI, Livdelzi, NERLYNX, OJJAARA, OPDUALAG, ORGOVYX, Orserdu, REBLOZYL, SARCLISA, Xtandi | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jakafi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error